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Breast cancer subtypes such as triple-negative that lack the expression of oestrogen recep-
tor (ER), progesterone receptor (PR) and human epidermal growth factor 2 receptor (HER2),
remain poorly clinically managed due to a lack of therapeutic targets. This necessitates iden-
tification and validation of novel targets. Suppression of Popeye domain-containing protein
1 (POPDC1) is known to promote tumorigenesis and correlate to poor clinical outcomes in
various cancers, and also promotes cardiac and skeletal muscle pathologies. It remains to
be established whether POPDC1 is dysregulated in breast cancer, and whether overcoming
the dysregulation of POPDC1 could present a potential therapeutic strategy to inhibit breast
tumorigenesis. We assessed the potential of POPDC1 as a novel target for inhibiting breast
cancer cell migration and proliferation. POPDC1 was significantly suppressed with reduced
cell membrane localization in breast cancer cells. Furthermore, functional suppression of
POPDC1 promoted breast cancer cell migration and proliferation, which were inhibited by
POPDC1 overexpression. Finally, cAMP interacts with POPDC1 and up-regulates its ex-
pression in breast cancer cells. These findings suggest that POPDC1 plays a role in breast
tumorigenesis and represents a potential therapeutic target or biomarker in breast cancer
medicine.
Introduction
Breast cancer is the second leading cause of cancer-related morbidity and mortality globally [1]. Despite
major progress in the development of new breast cancer treatments and in the clinical management of the
disease over the years, these have been met with major challenges including drug resistance [2-5]. Fur-
thermore, breast cancer is amolecularly heterogeneous diseasewith subtypes that have proven challenging
to target and which display varying levels of susceptibility to therapeutic agents [4,6,7]. This necessitates
identification and validation of novel therapeutic targets that can be targeted to deliver maximum clini-
cal efficacy withminimum side effects especially in poorlymanaged breast cancer subtypes. Breast cancer
can be classified on amolecular basis into five subtypes: luminalA, luminal B, HER2 positive, claudin-low
and basal-like, according to the expression levels of oestrogen receptors (ER), progesterone receptors (PR)
and human epidermal growth factor receptor 2 (HER2) in the cell. Luminal A tumours are ER+, PR+/−
and HER2−, luminal B tumours are ER+, PR+/− and HER2+, HER2 positive tumours are ER−, PR− and
HER2+. Basal-like tumours and claudin-low tumours are subclasses of triple negative breast cancer and
are ER−, PR− and HER2− [8]. Basal-like tumours are aggressive, have poor prognosis and are more chal-
lenging to therapeutically target due to a lack of hormone receptor expression. In contrast, luminal A
tumours have a more positive prognosis, are less aggressive and easier to treat due to the expression of
hormone receptors [6,8]. Here we assess the potential of Popeye domain-containing protein 1 (POPDC1)
(also known as blood vessel epicardial substance (BVES)), as a novel target for inhibiting cell migration
and proliferation in breast cancer. We use a non-malignant breast cell line (MCF10A), a less aggressive
luminal A breast cancer cell line (MCF7) and aggressive breast cancer cell lines MDA231 (also known as
MDA-MB-231) which is triple-negative and the HER2+ cell line (SKBR3).
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POPDC1 (also known as BVES), is a transmembrane protein encoded by the POPDC1 gene and is thought to
be a tumour suppressor that is dysregulated to promote malignant cell behaviour. Loss of POPDC1 expression has
been correlated with enhanced cancer cell proliferation, migration, invasion, metastasis, drug resistance and poor
patient survival in various human cancers [9-13]. Suppression of POPDC1 has further been shown to promote cell
migration and invasion in hepatocellular carcinoma, and to promote tumorigenesis in colorectal cancer [9,11]. In ad-
dition, loss of POPDC1 has been shown to promote colorectal cancer tumorigenesis via activation of c-Myc regulated
networks and activation of Wnt signalling [12]. Although the exact functional mechanisms of POPDC1 are poorly
understood, the known roles and correlations between POPDC1 with cancer and cardiovascular diseases have been
recently reviewed [14,15].
POPDC1 belongs to the POPDC gene family which has three isoforms: POPDC1, POPDC2 and POPDC3 which
encode the POPDC1, POPDC2 and POPDC3 proteins respectively. POPDC proteins are transmembrane proteins
normally tethered to the cell membrane as a dimer held together by a disulphide bond [13,16,17]. They contain an
extracellular amino terminus, three transmembrane domains and a cytoplasmic Popeye domain which binds cyclic
nucleotides. The Popeye domain is evolutionary conserved and has been shown to bind cAMP with high affinity.
The binding of cyclic adenosine monophosphate (cAMP) to the Popeye domain is thought to induce structural
changes in POPDC1 that affects protein function [16,18]. The signalling cascade downstream of POPDC1 has not yet
been determined. Although the role of POPDC1 in breast cancer tumorigenesis remains to be established, POPDC1
presents a realisticallydruggable target for various reasons. Firstly, POPDC1possesses a novelPopeyedomain (PFAM:
PF04831), which has not been identified in any other protein outside the POPDC protein family [14,18-20]. The
Popeye domain has been linked to POPDC protein functions such as binding cAMP and maintenance of epithelial
integrity [15,21]. For example, truncation of the protein following introduction of an early stop codon has been shown
to prevent localization of POPDC1 to the cell membrane and prevent POPDC1-mediated tight junctionmaintenance
[21]. Hence the Popeye domain can be targeted to potentially induce effects specific to POPDC signalling with less
ubiquitous side effects than targeting molecules such as cAMP. Secondly, the reduced expression of POPDC1 consis-
tently correlates to tumorigenesis in various cancers and to the promotion of cardiovascular andmuscular pathologies
[14-16,19]. POPDC1 can therefore potentially be targeted to stabilize the protein, prevent loss of function and with-
drawal from the membrane to reduce pathological consequences.
Cyclic adenosine monophosphate (cAMP) is a second messenger molecule involved in signal transduction of, for
example, G-protein-coupled receptors. cAMP is synthesized when the enzyme adenylyl cyclase catalyses the conver-
sion of adenosine triphosphate (ATP) to cAMP. In breast cancer, elevation of intracellular cAMP concentrations has
been shown to promote apoptosis and inhibit cell migration and invasion [22,23]. In addition, the elevation of intra-
cellular cAMP concentrations has been shown to inhibit breast tumour growth in mouse xenografts [24]. However,
it remains to be established whether cAMP regulates POPDC1 in breast cancer, and whether POPDC1 is involved in
cAMP-mediated inhibition of cell migration, invasion and tumour growth.
We hypothesize that dysregulation of POPDC1 promotes malignant phenotypes in breast cancer and that restora-
tion of POPDC1 can potentially inhibit cellmigration and proliferation, and revert cells to a lessmalignant phenotype.
To test this hypothesis, we firstly determined the expression levels of POPDC1 in breast cancer cells in comparison
with normal breast cells. Secondly, we assessed the effects of loss and gain of POPDC1 functions on breast cancer
cell migration and proliferation. Thirdly, we determined whether cAMP interacts with, and regulates the levels of
POPDC1 in breast cancer cells. Finally, we assessed whether cAMP-mediated inhibition of cell migration and prolif-
eration is potentially facilitated via POPDC1 signalling.
This paper demonstrates firstly the suppression and loss of cell membrane localization of POPDC1 in breast cancer
cells. Secondly, suppression of POPDC1 promotes cell migration and proliferation in breast cancer cells, which are
significantly inhibited by the overexpression of POPDC1. Thirdly, cAMP interacts with and regulates POPDC1 ex-
pression in breast cancer cells and finally, cAMP-mediated inhibition of breast cancer cell migration and proliferation
is potentially mediated via POPDC1 signalling.
Materials and methods
Cell culture
MCF10A cells (ATCC) were grown in mammary epithelial cell growth medium bullet kit (Lonza). MCF7 cells
(ATCC), MDA231 cells (ATCC) and SKBR3 cells (ATCC) were grown in Dulbecco’s Modified Eagle’s medium
(DMEM) (Sigma) supplemented with 10% foetal calf serum (FCS), 2 mM L-glutamine (PAA Laboratories) and 1%
penicillin/streptomycin (penicillin 10,000 units/ml; streptomycin 10 mg/ml) (BioSera). Cells were grown at 37◦C, 5%
CO2 in a sterile humidified incubator and passaged at≥80% confluence. MCF10A is a non-malignant breast cell line
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and MCF7 is a luminal A breast cancer cell line classified as ER+, PR+/- and HER2-. MDA231 is a basal-like triple
negative breast cancer cell line classified as ER-, PR- and HER2- and SKBR3 is a HER2+ cell line classified as ER-, PR-
and HER2+.
Western blot
Cells were lysed in RIPA (radioimmunoprecipitation assay) buffer containing 50 mM Tris/HCl at pH 8, 150 mM
sodium chloride, 0.1% Triton-X 100, 0.1% sodium dodecyl sulphate, 0.5% sodium deoxycholate, 0.5% Nonidet P-40,
1% protease inhibitor (Sigma) and 0.1% phosphatase inhibitor (Sigma). Lysates were subsequently homogenized
through a 25 gauge needle. Gel electrophoresis was performed on a 10% polyacrylamide gel and proteins were trans-
ferred onto a nitrocellulosemembrane (Biorad). Antibodies used for immunoblotting included rabbit anti-Popdc1 di-
luted 1:100 (Abcam), rabbit anti-phospho-CREB (Ser133) (Cell Signalling Technology) diluted 1:500, goat anti-rabbit
conjugated with horseradish peroxidase diluted 1:500 (Abcam) and mouse anti-β-actin-peroxidase diluted 1:10000
(Sigma). Pull-down assay membranes were stained with anti-Popdc1 diluted 1:30 (Abcam), anti-β-actin-peroxidase
diluted 1:5000 (Sigma) and goat anti-rabbit IgG conjugated with horseradish peroxidase diluted 1:100 (Abcam). Pro-
tein bands were detected with an ECL chemiluminescence reaction kit (ThermoScientific).
Immunocytochemistry
Sterile glass coverslips were pre-coated with 10 μg/ml poly-l-lysine (PLL) and dried under sterile conditions. A total
of 2 × 104 cells were seeded on sterile PLL-coated glass coverslips and incubated at 37◦C, 5% CO2 in a humidified
incubator overnight. Cells were fixed onto coverslips with 4% paraformaldehyde for 20 min prior to 10-min per-
meabilization with 0.5% Triton X-100. Coverslips were rinsed three times in PBS prior to blocking, and after each
step in the staining procedure. Non-specific binding sites were blocked with 5% BSA dissolved in PBS, for 30 min at
room temperature. Cells were subsequently stained overnight at 4◦C with CF-555 Phalloidin (Biotium) diluted 1:40
in PBS. Primary antibody staining with POPDC1 antibody (Sigma) (diluted 1:100) was subsequently performed with
overnight incubation at 4◦C. Secondary antibody staining was performed with Biotin-SP-conjugated goat anti-rabbit
secondary antibody diluted 1:250 (Abcam) for 1 h at room temperature. Tertiary antibody staining was subsequently
performed with Streptavidin-fluorescein diluted 1:150 (Abcam) for 30 min at room temperature. Counterstaining
with 0.1 μg/ml DAPI dilactate nuclear probe (Sigma) was performed in the dark at room temperature for 10 min.
Coverslips were mounted onto microscope slides with 1,4-diazabicyclo[2.2.2]octane (DABCO) mountant (Sigma),
and stored in the dark. Confocal images were captured in single confocal plane with a Zeiss LSM700 confocal mi-
croscope at 63× magnification and processed using Zeiss Zen Black software. POPDC1 fluorescence intensity was
measuredwith the ImageJ software. To quantitatively compare cellmembrane expression of POPDC1 relative to over-
all expression in individual cells, fluorescence from the POPDC1 proteinwasmeasured perμm2 in themembrane and
also across the whole cell. This was then presented as a comparative ratio of membrane fluorescence intensity/overall
cell fluorescence intensity.
Protein suppression with siRNA
A total of 2 × 104 cells per/ml were grown in complete medium 24 h prior to transient transfection with POPDC1
siRNA (Qiagen) or scrambled siRNA (Qiagen). Cells were incubated in serum-free medium 30 min prior to trans-
fection. siRNA was pre-mixed with Lipofectamine 2000 R© (Invitrogen) in serum-free medium for 20 min and added
to the cells. Complete medium was added to the cells 3 h post-transfection to minimize toxicity to the cells. Boy-
den chamber assay, Alamar Blue assay and Western blot analyses were performed 36 h post-transfection. Cells were
starved overnight prior to performing the Alamar Blue assay.
Generation of stable cell lines
mPOPDC1 cDNA containing aG418 resistance cassette was kindly gifted by Professor Thomas Brand (Imperial Col-
lege London). Plasmid DNA was transfected into MCF7, MDA231 and SKBR3 cells using Amaxa NucleofectorTM II
(Lonza) to generate cell lines stably overexpressing POPDC1; MCF7 POP1++, MDA POP1++ and SKBR3 POP1++.
Selection of stably transfected cells was performed with 1 mg/ml Geneticin sulphate (Biovision) (concentration ver-
ified using a kill curve) for 21 days. G418 (0.5 mg/ml) was added to complete growth medium to maintain selection
of MCF7 POP1++, MDA231 POP1++ SKBR3 POP1 ++ cell lines thereafter.
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Boyden migration assay
Boyden chamber migration assays were performed to assess cell migration using 8 μm pore polycarbonate mem-
branes (Neuro Probe Inc.). For experiments where the effects of POPDC1 knockdown and POPDC1 overexpression
on cell migration were assessed, lower wells of the Boyden chamber were loaded with serum-free medium lacking
any migrant solution to ensure that the observed difference in migration was due to the effects of the difference
in POPDC1 expression levels. For experiments where the effects of cAMP on cell migration were measured, lower
wells were loaded with 60 μM Sp-8-Br-cAMPS (in serum-free medium) for the test samples and simply serum-free
medium for the control samples. Cells were suspended in serum-free medium to a density of 2× 105 cells/ml prior to
loading into upper wells of the chamber. After a 3-h incubation at 37◦C and 5% CO2 in a sterile humidified incubator,
non-migrated cells were scraped from the membrane surface and migrated cells were stained with a Diff Quik stain-
ing kit (Medion Diagnostix AG). Stained cells were subsequently counted using a light microscope and representative




A total of 2 × 103 cells/well were seeded in 96-well plates and were serum starved overnight prior to drug treatment.
AlamarBlueR© dye (Thermoscientific) was added to each well at a final concentration of 10% (v/v) and cells were
incubated for 4 h at 37◦C and 5% CO2 in a sterile humidified incubator. Fluorimetric quantitation of the reduced
AlamarBlueR© dye was measured with a Biotek SynergyTM HT multi-detection microplate reader and Gen5 software
at 530 nm excitation and 590 nm emission wavelengths.
Pull-down assay
Cells were lysed in NP-40 lysis buffer containing 50 mM Tris at pH 7.5, 150 mM sodium chloride, 1% Nonidet P-40,
5% glycerol, 1% protease inhibitor and 0.1% phosphatase inhibitor. Lysates were subsequently homogenized through
a 25 gauge needle. Adenosine 3′,5′-cyclic monophosphate (cAMP) agarose beads (Sigma) weremixed with phosphate
buffered saline (PBS) at pH 7.4 to form a 50% slurry. cAMP agarose bead slurry (400 μl) was centrifuged in a PierceR©
spin cup (Thermo Scientific) at 1000×g for 1 min. Lysate (150 μl) was diluted with 150 μl of PBS at pH 7.4 and gently
mixed with cAMP agarose beads in a spin cup and incubated for 6 h at 4◦C with gentle agitation. The mixture was
subsequently centrifuged at 1000×g for 1 min to filter out the liquid phase of the lysate. The beads were washed with
150 μl of PBS at pH 7.4 and subjected to centrifugation at 1000×g for 1 min to wash off unbound elements from the
beads. Four additional washes were subsequently performed. To elute specifically bound proteins, beads were gently
mixed with 150 μl of elution buffer (0.1 M glycine at pH 2.5) and centrifuged at 1000×g for 1 min. Four elution steps
were performed separately. Neutralization buffer (5 μl; 1 M Tris at pH 8.0) was added to each eluted fraction for pH
neutralization. Western blot analysis was performed on the lysate, wash and elution fractions as previously described.
cAMP treatment
Cells were grown to 70% confluence in 6 or 9 cm tissue culture dishes prior to Sp-8-Br-cAMPS (Biolog) treatment.
Optimal drug concentration selection was performed with a range of Sp-8-Br-cAMPS concentrations; 20, 40 and
60 μM diluted in serum-free DMEM. Cells were incubated at 37◦C and 5% CO2 in a sterile humidified incubator
for 1 h. Time course analysis of the effects of Sp-8-Br-cAMPS on POPDC1 expression was performed with 60 μM
Sp-8-Br-cAMPS diluted in serum-free DMEM, over 1, 3 and 6 h incubation periods at 37◦C and 5% CO2 in a sterile
humidified incubator. Control samples were treated with serum-free medium. To assess whether up-regulation of
POPDC1 by cAMP pre-treatment affected cell proliferation, cells were treated with 60 μM Sp-8-Br-cAMPS for 1 h,
prior to replacement of the treatment solution with a fresh 60 μM Sp-8-Br-cAMPS solution and incubation for 24 h.
This two-phase treatment approach initially up-regulates POPDC1 (1st Sp-8-Br-cAMPS application), and then as-
sesses the functional impact of the high intracellular cAMP levels provided by the second Sp-8-Br-cAMPS application
on the up-regulated POPDC1 levels. Cell lysis and Western blot analysis were performed as described above.
Statistical analysis
Unpaired two-tailed Student’s t-test was performed on datasets with two comparison groups and one-way ANOVA
with Dunnett’s post hoc tests were performed on comparisons of more than two groups of data. A P-value ≤
0.05 was considered statistically significant. Statistical significance was classified as follows: *P≤0.05, **P≤0.01 and
***P≤0.001.
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Figure 1. POPDC1 is suppressed in breast cancer cells
Western blot analysis of POPDC1 expression in breast cell lines. POPDC1 is expressed at lower levels in malignant MDA231 and
SKBR3 cells in comparison with non-malignant MCF10A breast cells (n=3). Graph represents densitometric quantification of protein
bands. Protein bands were normalized by calculating the POPDC1/β-actin ratio. Normalized ratios for each cell line were expressed
as a ratio relative to MCF10A to show protein fold differences for each cell line relative to the MCF10A cells. Comparisons of protein
fold ratios were conducted using ANOVA with Dunnett’s post hoc test; *P≤0.05.
Results
The expression of POPDC1 is suppressed in breast cancer cell lines in
comparison with non-malignant cells
Suppression of POPDC1 at protein and mRNA level has been observed in various cancers [11-13,25]. We assessed if
POPDC1was suppressed in breast cancer cells in comparisonwith non-malignant breast cells. Interestingly, POPDC1
was significantly suppressed in the more aggressive breast cancer subtypes, MDA231 triple-negative cells and SKBR3
HER2+ cells, in comparison with non-malignant MCF10A cells (Figure 1).
Cell membrane localization of POPDC1 is reduced in breast cancer cell
lines
Cell membrane localization of POPDC1 is known to be observed in various epithelial cells [26], so we next as-
sessed if POPDC1 localization is dysregulated in malignant MCF7 and MDA231 breast cells in comparison with
non-malignant MCF10A breast cells (Figure 2). POPDC1 (green) co-localized with Phalloidin (red) and is localized
to the cell membrane of MCF10A non-malignant cells suggesting that POPDC1 is expressed primarily on the cell
membrane of MCF10A cells (Figure 2). This is consistent with its junctional function, and role in maintaining ep-
ithelial barrier integrity. Cell membrane expression of POPDC1 is significantly reduced in MDA231 cells and SKBR3
cells suggesting that the membrane localization of POPDC1 is reduced in triple negative and HER2+ breast cancer
cells. Loss of POPDC1 expression on the cell membrane could contribute to enhanced migration and malignant de-
velopment by loss of the POPDC1 role in the maintenance of epithelial integrity, loss of tight junction maintenance
and general molecular instability.
Suppression of POPDC1 promotes cell migration and proliferation in
breast cancer cells
Suppression of POPDC1 has been shown to promote cell migration, proliferation and invasion in various human
cancer cells and tumour multiplicity in mice [11,12,25]. To determine if suppression of POPDC1 affects breast can-
cer cell migration and proliferation, POPDC1 was suppressed with POPDC1 siRNA in MCF7, MDA231 and SKBR3
cells (Figure 3A). A significant increase in cell migration was observed following suppression of POPDC1 in MCF7,
MDA231 and SKBR3 cells (Figure 3B). Furthermore, suppression of POPDC1 significantly promoted cell prolifer-
ation in the more aggressive breast cancer cell lines MDA231 and SKBR3 (Figure 3C). This dataset suggests that
suppression of POPDC1 promotes cell migration and proliferation in breast cancer cells and further supports the
hypothesis that dysregulation of POPDC1 promotes a more malignant phenotype in breast cancer.
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Figure 2. POPDC1 membrane localization is reduced in cancer cells
(A) Cell membrane expression of POPDC1 is reduced in breast cancer cell lines. Immunocytochemical analysis of cell membrane
expression of POPDC1 in breast cancer cells. Cells were counterstained with CF-555 Phalloidin (red) for visualization of filamentous
actin on the cytoskeleton and nuclear probe DAPI (blue). In MCF10A non-malignant cells, regions of high POPDC1 (green) local-
ization on the plasma membrane (white arrows) are observed. Plasma membrane expression of POPDC1 is reduced in MDA231
and SKBR3 cells (white arrows indicate POPDC1 located in other cellular locations in these images); scale bars = 20 μm. (B)
Quantitative analysis of the membrane expression of POPDC1 in different cell lines. Membrane POPDC1 fluorescence intensity
per μm2 was measured for individual cells along with fluorescence intensity per μm2 across the whole cell. This was then con-
verted to a ratio of fluorescence intensity in the membrane/fluorescence intensity across the entire cell. Membrane expression of
POPDC1 is significantly reduced in MDA231 and SKBR3 cells compared with non-malignant MCF10A cells (n=4). Comparisons
were conducted using ANOVA with Dunnett’s; *P≤0.05, **P≤0.01.Data are presented as mean ratio +− SEM.
6 c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
License 4.0 (CC BY).
Bioscience Reports (2017) 37 BSR20171039
https://doi.org/10.1042/BSR20171039
Figure 3. Suppression of POPDC1 promotes cell migration and proliferation in breast cancer cells
(A) Western blot analysis of POPDC1 expression following transfection with POPDC1 siRNA confirmed POPDC1 suppression in
MCF7 (n=3), MDA231 (n=3) and SKBR3 (n=3) cells. Graphs below image panels represent densitometric quantification of protein
bands. Protein bands were normalized by calculating the POPDC1/β-actin ratio. Normalized ratios were subsequently expressed
as a ratio relative to control bands (no siRNA) to determine protein fold changes. (B) Suppression of POPDC1 with POPDC1
siRNA significantly promoted cell migration in MCF7 (n=5), MDA231 cells (n=5) and SKBR3 cells (n=5). Boyden chamber assay
was performed over a 3-h incubation period to allow cell migration across the polycarbonate membrane; scale bars = 250 μm. (C)
Suppression of POPDC1with POPDC1 siRNA significantly promoted cell proliferation inMDA231 cells (n=5) and SKBR3 cells (n=5),
but not in MCF7 cells (n=4). Cells were transfected for 36 h prior to overnight starvation in serum-free medium and subsequent
incubation in 10%AlamarBlue
R©
dye for 4 h. Comparisons of protein fold change ratios, mean%migration andmean% proliferation
were conducted using ANOVA with Dunnett’s post hoc test. Mean values presented +− SEM; **P≤0.01, ***P≤0.001.
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Overexpression of POPDC1 suppresses cell migration and proliferation in
breast cancer cell lines
We next assessed if gain of POPDC1 function would inhibit cell migration and proliferation. Due to a lack of avail-
able POPDC1 activators or modulators, gain of function studies were conducted by overexpression of POPDC1 into
MCF7, MDA231 and SKBR3 cells (Figure 4A).
Given that overexpression of POPDC1 has been shown to attenuate colorectal cancer tumour growth and metas-
tasis in mice [12], we next asked if POPDC1 overexpression affects breast cancer cell migration and proliferation.
Overexpression of POPDC1 significantly inhibited cell migration and proliferation in MCF7, MDA231 and SKBR3
cells (Figure 4B and C), consistent with our theory that POPDC1 suppresses malignant cell behaviour.
cAMP interacts with and up-regulates POPDC1 in breast cancer cells
The Popeye domain of POPDC1 has been shown to bind cAMP with high affinity using radioligand binding assays
and affinity precipitation [16]. The interaction between POPDC1 and cAMP has not been reported in breast cancer
cells. To confirm if cAMP interacts with POPDC1 in breast cancer cells, we performed a pull-down assay with cAMP
agarose beads. To confirm specificity of the assay, lysates were further probed for β-actin, which is known to not
interact with cAMP.
POPDC1 was detected in the first and second eluted fractions of cAMP agarose pull-down assays in MCF7,
MDA231 and SKBR3 cells. The eluted fractions contain proteins that interact with cAMP. Presence of POPDC1 in
the eluted fraction confirms that POPDC1 indeed interacts with cAMP in MCF7, MDA231 and SKBR3 cells, and
is pulled out of the lysate using immobilized cAMP (Figure 5A). Furthermore, the negative control β-actin was de-
tected in the lysate fraction containing unbound proteins, but not in the eluted fractions confirming that the assay
specifically eluted cAMP bound proteins. To assess the effects of cAMP on POPDC1 expression in breast cancer cells,
we next asked if up-regulation of cAMP with the cAMP analogue Sp-8-Br-cAMPS can affect the levels of POPDC1.
The effects of a range of Sp-8-Br-cAMPS concentrations were assessed over 1 h treatment duration (Figure 5B). De-
tection of POPDC1 was up-regulated by 40 and 60 μM Sp-8-Br-cAMPS in MCF7 cells, significantly up-regulated
by 20, 40 and 60 μM Sp-8-Br-cAMPS in MDA231 cells and by 40 and 60 μM Sp-8-Br-cAMPS in SKBR3 cells. To
confirm activation of the cAMP pathway, we assessed if 20, 40 and 60 μM Sp-8-Br-cAMPS affects the expression of
phospho-CREB, another molecule that functions downstream of cAMP. Treatment with different Sp-8-Br-cAMPS
concentrations increased the expression levels of phospho-CREB in MCF7, MDA231 and SKBR3 cells confirming
activation of cAMP signalling (Figure 5B). This dataset confirms that cAMP indeed interacts with POPDC1 and can
increase its presence and stability in breast cancer cells.
cAMP inhibits cell migration and proliferation in breast cancer cells
Increasing intracellular levels of cAMPhas been shown to inhibit breast cancer cellmigration and invasion [22,23].We
asked if increasing intracellular levels of cAMPwith 60μM Sp-8-Br-cAMPS affects cellmigration and proliferation in
MCF7,MDA231 and SKBR3 cells. Sp-8-Br-cAMPS (60μM) significantly inhibited cellmigration inMCF7,MDA231
and SKBR3 cells (Figure 6A) and cell proliferation in SKBR3 cells (Figure 6B). However, no effect was observed on
MCF7 and MDA231 cell proliferation. We hypothesized that the initial treatment with Sp-8-Br-cAMPS served to
up-regulate the expression of POPDC1, but that insufficient concentrations then remained to actually act on the
up-regulated protein due to the gradual degradation of the analogue. Therefore, we applied a further 60 μM after an
hour to seewhat functional effects were evident when POPDC1 expressionwas raised. Following this two-phase treat-
ment regimen, significant inhibition of cell proliferation was observed in MCF7, MDA231 and SKBR3 cells (Figure
6C). Taken together this dataset suggests that increasing intracellular levels of cAMP inhibits cell migration and pro-
liferation, and that high cellular POPDC1 expression interacts with cAMP to inhibit cell proliferation. It also suggests
that cAMP control of cell migration and proliferation varies in sensitivity suggesting mechanistically diverse effects.
Suppression of POPDC1 is overcome by SP-8-Br-cAMPS and this rescues
inhibited cell migration and proliferation
Although the dataset so far suggests that cAMP-mediated inhibition of cell migration and proliferation is potentially
facilitated via POPDC1 signalling, cAMP-mediated signals could be facilitated via other cAMP-binding molecules
such as POPDC2 and POPDC3. It is therefore essential to determine whether cAMP-mediated suppression of breast
cancer cell migration and proliferation is indeed dependent on cAMP-induced increase in POPDC1 protein levels.
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Figure 4. Overexpression of POPDC1 suppresses breast cancer cell migration and proliferation
(A) Western blot analysis of POPDC1 expression in wild-type cells and cell lines stably transfected with POPDC1; MCF7 POP1++,
MDA231 POP1++ and SKBR3 POP1++. Stably transfected cell lines expressed significantly higher levels of POPDC1 MCF7 (n=4),
MDA231 (n=4) and SKBR3 (n=4). Graphs below Western blot band panels represent densitometric quantification of protein bands.
Protein bands were normalized by calculating the POPDC1/β-actin ratio. Fold differences in protein expression were calculated by
expressing normalized band values of POPDC1 overexpressing cell lines as a ratio to normalized band values of wild-type cell lines.
(B) Overexpression of POPDC1 significantly suppressed cell migration in MCF7 cells (n=4), MDA231 (n=5) and SKBR3 cells (n=5).
Boyden chamber assay was performed over a 3-h incubation period to allow cell migration across the polycarbonate membrane;
scale bars = 250 μm. (C) Overexpression of POPDC1 significantly suppressed cell proliferation in MCF7 cells (n=4), MDA231 cells
(n=5) and SKBR3 cells (n=5). Cells were starved in serum-free medium overnight prior to incubation in 10% AlamarBlueR© dye for
4 h. Comparisons of protein fold change ratios, mean % migration and mean % proliferation were conducted using an unpaired
t-test. Mean values presented +− SEM; **P≤0.01, ***P≤0.001.
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 5. cAMP interacts with POPDC1 and up-regulates its expression in breast cancer cells
(A) Western blot analyses of cAMP agarose pull-down assays in MCF7, MDA231 and SKBR3 cells. POPDC1 was detected at high
levels in the first eluted fraction (eluate 1) and at very low levels in the second eluted fraction (eluate 2) in MCF7 (n=3), MDA231 (n=3)
and SKBR3 (n=3) cells confirming protein interaction between POPDC1 and cAMP. β-Actin, the negative control, was detected
in the unbound protein fraction but not in the eluted fractions, confirming specificity of the assay. (B) Western blot analysis of the
effects of 20, 40 and 60 μM Sp-8-Br-cAMPS on the expression of POPDC1 and CREB following 1 h treatment duration in MCF7
(n=3), MDA231 (n=3) and SKBR3 (n=3) cells. Graphs below Western blot band panels represent densitometric quantification of
POPDC1 bands as a ratio to corresponding β-actin bands. Comparisons of normalized β-actin/POPDC1 ratios were conducted
using ANOVA with Dunnett’s post hoc test. Mean values presented +− SEM; *P≤0.05, **P≤0.01, ***P≤0.001.
Hence, we next asked if the POPDC1 suppression attenuates cAMP-mediated breast cancer cell migration and pro-
liferation in these cell lines. To test this, the effects of 60 μM Sp-8-Br-cAMPS on breast cancer cell migration and
proliferation were assessed following POPDC1 knockdown in MCF7, MDA231 and SKBR3 cells (Figure 7).
POPDC1 knockdown failed to alter cAMP-induced cellmigration and proliferation inMCF7,MDA231 and SKBR3
cells (Figure 7A and B) with migration and proliferation levels unchanged relative to baseline. This confirms that
cAMP-mediated inhibition of breast cancer cell migration and proliferation depends on high cellular POPDC1 pro-
tein levels and is in line with the present finding that cAMP upregulates POPDC1, and does so to the extent that it
overcomes the siRNA mediated downregulation induced in Figure 6 and 7 to rescue migration and proliferation to
control levels.
Discussion
In the present study, we have shown that POPDC1 is expressed in breast cells, but the expression is significantly
suppressed in aggressiveMDA231 and SKBR3 breast cancer cells, in comparisonwith non-malignantMCF10Abreast
cells (Figure 1). This is consistent with suppression of POPDC1 protein and mRNA observed in various cancers
including gastric cancer, colorectal cancer and hepatocellular carcinoma [11-13].
The present study has further demonstrated differential POPDC1 localization in breast cancer cells in comparison
with non-malignant breast cells. Cell membrane localization of POPDC1 is reduced in MDA231 and SKBR3 cells
in comparison with localization of POPDC1 to the cell membrane in normal MCF10A breast cells (Figure 2). We
hypothesize that suppression of POPDC1 expression in breast cancer cells prevents the POPDC1 functioning at the
10 c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
License 4.0 (CC BY).
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Figure 6. Sp-8-Br-cAMPS inhibits cell migration and proliferation in breast cancer cell lines
(A) Boyden chamber assay analysis of the effects of 60 μMSp-8-Br-cAMPS on breast cancer cell migration in MCF7 (n=4), MDA231
(n=4) and SKBR3 (n=4) cells. Boyden chamber assay was performed over a 3-h incubation period to allow cell migration across
the polycarbonate membrane; scale bars = 250 μm. (B) Alamar Blue assay analysis of the effects of 60 μM Sp-8-Br-cAMPS on
MCF7 (n=4), MDA231 (n=4) and SKBR3 (n=4) cell proliferation. Cells were starved in serum-free medium overnight prior to drug
treatment. (C) Alamar Blue assay analysis of the effects of a two-phase treatment with 60 μM Sp-8-Br-cAMPS on MCF7 (n=5),
MDA231 (n=5) and SKBR3 (n=5) cell proliferation. Cells were starved in serum-free medium overnight prior to drug treatment. Cells
were subsequently treated with 60 μM Sp-8-Br-cAMPS for 1 h prior to treatment replacement with a fresh 60 μM Sp-8-Br-cAMPS
solution and a further 24-h incubation. Alamar Blue assays were performed by incubating cells in 10% AlamarBlue
R©
dye (diluted
in serum-free medium) for 4 h. Mean % migration and mean % proliferation values were compared using an unpaired t-test. Mean
values presented +− SEM; **P≤0.01, ***P≤0.001.
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 7. Suppression of POPDC1 is overcome by SP-8-Br-cAMPS and rescues inhibited cell migration and proliferation in
breast cancer cells
(A) Boyden chamber assay analysis of the effects of 60 μMSp-8-Br-cAMPS onMCF7 (n=4), MDA231 (n=4) and SKBR3 (n=4) breast
cancer cell migration following POPDC1 suppression with siRNA. Boyden chamber assay was performed over a 3-h incubation
period to allow cell migration across the polycarbonate membrane; scale bars = 250 μm. (B) Alamar Blue assay analysis of the
effects a two-phase 60 μM Sp-8-Br-cAMPS treatment on the proliferation of MCF7 (n=5), MDA231 (n=5) and SKBR3 (n=5) cells
following POPDC1 suppression with siRNA. Cells were transfected for 36 h and starved overnight prior to drug treatment. Cells
were treated with 60 μM Sp-8-Br-cAMPS treatment for 1 h prior to treatment replacement with a fresh 60 μM Sp-8-Br-cAMPS
treatment solution and 24-h incubation. Alamar Blue assay was performed by incubating cells in 10% AlamarBlue
R©
dye for 4 h.
Mean % migration and mean % proliferation values were compared using an unpaired t-test. Mean values presented +− SEM.
cell membrane. Suppression of POPDC1 on the cell membrane has been shown to impair POPDC1-mediated tight
junction maintenance in epithelial cells [21]. We postulate that the absence of functional POPDC1 dimers on breast
cancer cell membranes potentially leads to a reduction in POPDC1-mediated tight junction maintenance thereby
promoting cell migration.
We have further demonstrated the functional relevance of POPDC1 dysregulation in breast cancer. Suppression
of POPDC1 significantly promotes a malignant phenotype in breast cancer by promoting cell migration in MCF7,
MDA231 and SKBR3 cells, and cell proliferation in the more aggressive MDA231 and SKBR3 cells (Figure 3B and C).
Additionally, the overexpression of POPDC1 reverts cells to a lessmalignant phenotype by significantly inhibiting cell
migration and proliferation in MCF7, MDA231 and SKBR3 breast cancer cells. Taken together with data from other
12 c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
License 4.0 (CC BY).
Bioscience Reports (2017) 37 BSR20171039
https://doi.org/10.1042/BSR20171039
studies which show that the suppression of POPDC1 promotes cell migration and invasion in glioblastoma, hepato-
cellular carcinoma, gastric cancer and colorectal cancer [12,13,25,27], these data provide strong evidence to support
the hypothesis that the dysregulation of POPDC1 promotes malignant phenotypes in breast cancer. Loss of POPDC1
expression has been shown to not only promote malignant behaviour in cancer, but also promote cardiac and skeletal
muscle pathologies, which are inhibited or partially reversed by gain of POPDC1 function [14,16,19]. These suggest
that POPDC1 could potentially be therapeutically targeted in a similar manner to treat various diseases. Therapeutic
targeting to prevent POPDC1 dysregulation or to promote gain of POPDC1 function can potentially be achieved in
various ways. Firstly, gain of function could be achieved with small molecules that bind to the Popeye domain to
induce protein stabilization. Secondly, truncation of the protein has been shown to prevent POPDC1-mediated tight
junction maintenance by preventing localization of POPDC1 to the cell membrane [21]. Loss of POPDC1 function
can therefore potentially be prevented by targeting mutations that prevent protein localization to the cell membrane
or stabilizing the protein in the membrane.
The present study has further shown that cAMP interacts with POPDC1 and up-regulates its expression in MCF7,
MDA231 and SKBR3 breast cancer cells (Figure 5A and B). Furthermore cAMP significantly inhibited cell migration
in MCF7, MDA231 and SKBR3 cells (Figure 6A), consistent with data from other studies showing that cAMP inhibits
cellmigration and invasion in breast cancer cells [22,23].However, significant inhibition of cell proliferation inMCF7
and MDA231 cells was only observed following a two-phase treatment regimen with 60 μM Sp-8-Br-cAMPS (Figure
6C). The initial Sp-8-Br-cAMPS treatment served to up-regulate the expression of POPDC1, with the subsequent
treatment permitting the functional consequences of Sp-8-Br-cAMPS binding to elevated POPDC1 expression to be
measured. This suggests cAMP-mediated cell proliferation is facilitated via a mechanism that at least in part involves
the up-regulation of POPDC1. The hypothesis that cAMP-mediates inhibition of breast cancer cell migration and
proliferation via POPDC1 signalling is further strengthened by restoration of the cell migration and proliferation
in MCF7, MDA231 and SKBR3 cells by elevating cAMP following POPDC1 knockdown (Figure 7A and B) which
suggests that these effects are dependent upon a cAMP-induced increase in POPDC1 levels. Furthermore, it suggests
that migration does not require the up-regulation of POPDC1 as it was inhibited by a single treatment. This is con-
sistent with a mechanism that involves direct action of Sp-8-Br-cAMPS in stabilizing the existing POPDC1 protein
being sufficient to reducemigration. It further suggests a more complex and less direct mechanism involved in cAMP
potentially exerting control of proliferation via POPDC1. This firstly requires up-regulation of the protein, and sub-
sequent interaction with cAMP to influence proliferation perhaps via a downstreammoiety. This molecular diversity
is a novel and interesting finding that may further extend the therapeutic potential of POPDC1 as a target.
In conclusion, POPDC1 represents a druggable target that can potentially be manipulated to inhibit breast cancer
cell migration and proliferation. In particular, this seems possible by binding of the cAMP-binding Popeye domain,
which seems to establish protein function in the plasma membrane. As a unique molecular domain, molecules that
can interact in a cAMP-mimicking manner seem like exciting candidates for investigation going forward. However,
mechanisms by which POPDC1 regulates cell migration and proliferation in breast cancer need to be clearly eluci-
dated in order to permit development of directed therapeutics to take advantage of POPDC1 and its diversemolecular
role.
Highlights
• Expression and cell membrane localization of POPDC1 is reduced in breast cancer cells.
• Suppression of POPDC1 promotes breast cancer cell migration and proliferation.
• Overexpression of POPDC1 inhibits breast cancer cell migration and proliferation.
• cAMP interacts with, and up-regulates POPDC1 in breast cancer..
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